Two U.K. health ministers are calling on Vertex Pharmaceuticals (VRTX) to provide an “urgent resolution” to negotiations over access to its cystic fibrosis drug, a battle that has lingered for two years and caused a ruckus among patients and government officials.

The company should “commit to pricing that is responsible and proportionate to the benefits that patients receive,” and provide “all available data supporting the cost effectiveness” of its most recent proposal to the government, according to an April 19 letter from Steve Brine, the under secretary of state for public health and primary care, and Lord O’Shaughnessy, the under secretary of state for health. A Vertex spokeswoman wrote us to say that a meeting with the National Health Service is scheduled for this week.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy